• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . Multicenter evaluation of molecular point-of-care testing and digital immunoassays for influenza virus A/B and respiratory syn

tetano

Editor, Senior Moderator
J Infect Chemother


. 2021 Jan 25;S1341-321X(21)00018-0.
doi: 10.1016/j.jiac.2021.01.010. Online ahead of print.
Multicenter evaluation of molecular point-of-care testing and digital immunoassays for influenza virus A/B and respiratory syncytial virus in patients with influenza-like illness


Norihito Kaku[SUP] 1 [/SUP], Hina Kodama[SUP] 2 [/SUP], Norihiko Akamatsu[SUP] 2 [/SUP], Kenji Ota[SUP] 3 [/SUP], Kosuke Kosai[SUP] 3 [/SUP], Yoshitomo Morinaga[SUP] 4 [/SUP], Yusuke Narita[SUP] 5 [/SUP], Yasushi Matsumoto[SUP] 6 [/SUP], Tetsuro Matsushita[SUP] 7 [/SUP], Yohei Mizuta[SUP] 8 [/SUP], Koichi Izumikawa[SUP] 9 [/SUP], Hiroshi Mukae[SUP] 10 [/SUP], Katsunori Yanagihara[SUP] 3 [/SUP]



Affiliations

Abstract

Introduction: Digital immunoassays (DIAs) and molecular point-of-care (POC) tests for influenza were recently developed. We aimed to evaluate and compare the positive rate with molecular POC tests and DIAs in detecting influenza virus A, B and respiratory syncytial virus (RSV).
Methods: A prospective observational study was conducted in 2019-2020. Nasopharyngeal swab samples were collected from adult outpatients with influenza-like illness who visited four hospitals and clinics in Japan. DIAs were performed at each facility. The clinical diagnosis was determined based on the findings of DIAs, history taking, and physical assessment. Molecular POC test and reverse transcription polymerase chain reaction (RT-PCR) were performed later.
Results: A total of 182 patients were evaluated. The positive rate for influenza virus with molecular POC test was significantly higher than that with DIAs (51.6% versus 40.7%, p = 0.046). In patients who tested positive for influenza virus with only molecular POC test, the presence of influenza virus was confirmed by RT-PCR. In a comparison between the patients who were positive for influenza virus with only molecular POC test and those with both molecular POC test and DIA, the percentage of patients who sought consultation within 18 h after the onset of symptoms was significantly higher in the molecular POC test only group than in the both methods group (70.0% versus 43.2%, p = 0.044).
Conclusions: A molecular POC test could contribute to the accurate diagnosis of influenza in patients with influenza-like illness, especially those who visited a hospital immediately after the onset of symptoms.

Keywords: Influenza; Molecular diagnostic techniques; Multicenter study; Point-of-care; Respiratory syncytial virus.
 
Back
Top Bottom